piracetam has been researched along with Dyskinesia, Medication-Induced in 16 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia." | 3.72 | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. ( Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A, 2004) |
| "Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover." | 2.76 | Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. ( Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G, 2011) |
| "Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties." | 2.76 | A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. ( Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK, 2011) |
| "Piracetam is a potent antioxidant, a cerebral neuroprotector, a neuronal metabolic enhancer, and a brain integrative agent." | 2.73 | Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. ( Bersudsky, Y; Dwolatzky, T; Lerner, V; Libov, I; Miodownik, C, 2007) |
| "Levetiracetam was well tolerated." | 2.73 | Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ( Baker, CB; Cohen, SJ; Saksa, JR; Tek, C; Woods, SW, 2008) |
| "Treatment with levetiracetam 250 mg orally b." | 1.35 | Treatment of tardive dyskinesia with levetiracetam in a transplant patient. ( Abu-Elmagd, KM; Bond, G; Costa, G; Zivković, SA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozdemir, O | 1 |
| Baytan, B | 1 |
| Gunes, AM | 1 |
| Okan, M | 1 |
| Chen, PH | 1 |
| Liu, HC | 1 |
| Stathis, P | 1 |
| Konitsiotis, S | 1 |
| Tagaris, G | 1 |
| Peterson, D | 1 |
| Wong, KK | 1 |
| Alty, JE | 1 |
| Goy, AG | 1 |
| Raghav, S | 1 |
| Reutens, DC | 1 |
| Kempster, PA | 1 |
| McGavin, CL | 1 |
| John, V | 1 |
| Musser, WS | 1 |
| Bezard, E | 1 |
| Hill, MP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Michel, A | 1 |
| Grimée, R | 1 |
| Klitgaard, H | 1 |
| Tousi, B | 1 |
| Subramanian, T | 1 |
| Zesiewicz, TA | 1 |
| Sullivan, KL | 1 |
| Maldonado, JL | 1 |
| Tatum, WO | 1 |
| Hauser, RA | 1 |
| Bona, JR | 1 |
| Libov, I | 1 |
| Miodownik, C | 1 |
| Bersudsky, Y | 1 |
| Dwolatzky, T | 1 |
| Lerner, V | 1 |
| Zivković, SA | 1 |
| Costa, G | 1 |
| Bond, G | 1 |
| Abu-Elmagd, KM | 1 |
| Woods, SW | 1 |
| Saksa, JR | 1 |
| Baker, CB | 1 |
| Cohen, SJ | 1 |
| Tek, C | 1 |
| Kabes, J | 1 |
| Sikora, J | 1 |
| Starý, O | 1 |
| Pisvejc, J | 1 |
| Hanzlícek, L | 1 |
| Yonchev, V | 1 |
| Toreva, D | 1 |
| Margova, L | 1 |
| Yonchev, A | 1 |
| Fehr, C | 1 |
| Dahmen, N | 1 |
| Klawe, C | 1 |
| Eicke, M | 1 |
| Szegedi, A | 1 |
| Chaturvedi, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study[NCT00190008] | Phase 3 | 40 participants | Interventional | 2003-08-31 | Completed | ||
| [NCT00291213] | Phase 3 | 50 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for piracetam and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyski | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Ind | 2011 |
Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Leveti | 2006 |
Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced | 2007 |
Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Algorithms; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Adminis | 2008 |
[Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans | 1983 |
10 other studies available for piracetam and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Involuntary movements during vitamin B12 treatment.
Topics: Anticonvulsants; Clonazepam; Dyskinesia, Drug-Induced; Female; Humans; Infant; Male; Piracetam; Seve | 2010 |
Rapid improvement of neuroleptic-induced tardive dyskinesia with levetiracetam in an interictal psychotic patient.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levetiracetam; Mi | 2010 |
Levetiracetam as a treatment for tardive dyskinesia: a case report.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Antidepressive Agents; Chronic Disease; Clonidine; Depre | 2003 |
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
Topics: Animals; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induc | 2004 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
Topics: Aged; Anticonvulsants; Antiemetics; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Metoclo | 2008 |
The effect of some neurotropic drugs on neuroleptic hypersensitivity of dopamine receptors in the central nervous system.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Cyclophosphamide; Drug Hypersensitivi | 1980 |
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2001 |
Piracetam for drug-induced dyskinesia.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Dyskinesia, Drug-Induced; Female; Humans; Piracetam; Pyrrol | 1987 |